Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 1031 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103830]
2.Tiene citas relacionadas Cita con resumen
Zhou J, Wang X, Lee S, Wu WKK, Cheung BMY, Zhang Q, Tse G. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut 2020:diciembre. [Ref.ID 103806]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton-pump inhibitors. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103795]
4. Cita con resumen
Zhang X-Y, Wu H-B, Ling Y, Qian Z-P, Chen L. Analysis of the effect of proton pump inhibitors on the course of common COVID-19. medRxiv 2020:13 de junio. [Ref.ID 103794]
5. Cita con resumen
Jimenez L, Campos Codo A, de Souza Sampaio V, Oliveira AER, Kobo Ferreira LK, Gastao Davanzo G, et al.. The influence of pH on SARS-CoV-2 infection and COVID-19 severity. medRxiv 2020:. [Ref.ID 103792]
6. Cita con resumen
Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, Hospital-Guardiola I, de Diego-Cabanes C, Bejarano-Romero F, Rovira-Veciana D, Basora-Gallisa J. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. The Journal of Clinical Hypertension 2020;22:agosto. [Ref.ID 103791]
7.Enlace a cita original Cita con resumen
Li G-F, An X-X, Yu Y, Jiao L-R, Canarutto D, Yu G, Wang G, Wu D-N, Xiao Y. Do proton pump inhibitors influence SARS-CoV- 2 related outcomes? A meta-analysis. Gut 2020:10 de noviembre. [Ref.ID 103790]
8.Enlace a cita original Cita con resumen
Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:30 de julio. [Ref.ID 103733]
9.Enlace a cita original Cita con resumen
Haugaard JH, Kofoed K, Gislason G, Dreyer L, Egeberg A. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol 2020;156:2 de septiembre. [Ref.ID 103711]
10. Cita con resumen
Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [Ref.ID 103643]
11.Enlace a cita original Cita con resumen
Wang Y-H, Wintzell V, Ludvigsson JF, Svanström H, Pasterenak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatrics 2020;174:junio. [Ref.ID 103566]
12.Enlace a cita original Cita con resumen
13. Cita con resumen
Lassalle M, Le Tri L, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [Ref.ID 103532]
14. Cita con resumen
Khan MA, Yuan Y, Iqbal U, Kamal S, Khan M, Khan Z, Lee W, Howden CW. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. The American Journal of Gastroenterology 2020;115:mayo. [Ref.ID 103525]
15.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
16.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]
18.Enlace a cita original Cita con resumen
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]
20.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
Seleccionar todas
 
 1 a 20 de 1031 siguiente >>